PTCHF PureTech Health plc IFRS Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1782999 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.83M | $3.33M |
| R&D expense | $69.45M | $96.23M |
| SG&A expense | $71.47M | $53.30M |
| Operating income | -$136.09M | -$146.20M |
| Interest expense | $1.73M | $3.42M |
| Pretax income | $23.77M | -$36.10M |
| Income tax | -$4.01M | $30.52M |
| Net income | $53.51M | -$65.70M |
| EBITDA | -$132.52M | -$141.27M |
| EPS (basic) | 0.21 | -0.24 |
| EPS (diluted) | 0.21 | -0.24 |
| Weighted avg. shares (diluted) | 256.03M | 276.30M |
| Balance sheet | ||
| Cash & equivalents | $280.64M | $191.08M |
| Receivables | $1.52M | $2.38M |
| Current assets | $386.26M | $347.20M |
| PP&E, netmay include right-of-use assets (IFRS) | $7.07M | $9.54M |
| Intangibles | — | $906,000 |
| Total assets | $602.63M | $693.97M |
| Current liabilities | $41.39M | $51.37M |
| Short-term debt | — | $0 |
| Long-term debt | — | $0 |
| Total debt | — | $0 |
| Total liabilities | $194.70M | $235.74M |
| Shareholders' equity | $414.71M | $464.07M |
| Net debt | — | -$191.08M |
| Shares outstanding | — | 271.85M |
| Cash flow statement | ||
| Operating cash flow | -$134.37M | -$105.92M |
| Capital expenditure | $11,000 | $70,000 |
| Free cash flow | -$134.38M | -$105.99M |
| Investing cash flow | $240.89M | $68.99M |
| Financing cash flow | -$16.96M | $78.14M |
| Depreciation & amortization | $3.57M | $4.93M |
| Stock-based compensation | $22.85M | $4.42M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.